A 58-year-old man with biopsy-proven prostate cancer (Gleason 7, PSA 12 ng/mL) is being staged for treatment planning. He is asymptomatic with no bone pain. Which investigation is most appropriate to assess for distant metastases?

Explanation

## Staging Investigation for Prostate Cancer Metastases **Key Point:** PSMA PET-CT (or Choline PET-CT) is the most sensitive and specific imaging modality for detecting bone and soft tissue metastases in intermediate-to-high-risk prostate cancer. ### Risk Stratification & Staging Indications **High-Yield:** Staging investigations are indicated when: - PSA >10 ng/mL - Gleason score ≥7 - Clinical stage T2c or higher - Risk of metastases >15% (D'Amico criteria) This patient meets multiple criteria (Gleason 7, PSA 12 ng/mL) → staging is mandatory. ### Comparison of Imaging Modalities | Modality | Sensitivity | Specificity | Advantages | Limitations | |---|---|---|---|---| | **PSMA PET-CT** | **95–98%** | **95–97%** | **Gold standard; detects bone, soft tissue, nodal disease; high specificity** | **Cost; availability; not universally available in India** | | **Choline PET-CT** | 85–90% | 85–90% | Good for bone and nodal metastases | Lower sensitivity than PSMA | | **Bone scan (Tc-99m)** | 70–75% | 60–65% | Widely available; inexpensive | Lower sensitivity; poor specificity; false positives with arthritis, trauma | | **Plain radiographs** | 40–50% | Variable | Inexpensive | Very low sensitivity; detects only lytic/sclerotic lesions | | **Serum markers** | N/A | N/A | Supportive only | Cannot localize disease; non-specific | **Clinical Pearl:** PSMA (prostate-specific membrane antigen) PET-CT is revolutionizing prostate cancer staging. It detects: - Bone metastases (osteoblastic and osteolytic) - Soft tissue and nodal disease - Recurrent disease in biochemical relapse Sensitivity increases with PSA level: at PSA >10 ng/mL, PSMA PET-CT detects metastases in ~40–50% of patients. ### Current Practice Algorithm ```mermaid flowchart TD A[Biopsy-proven PCa]:::outcome --> B{Risk stratification}:::decision B -->|Low risk| C[No staging imaging]:::action B -->|Intermediate/High risk| D{PSA level & Gleason}:::decision D -->|PSA >10 or Gleason ≥7| E[PSMA PET-CT preferred]:::action E --> F[If PSMA unavailable: Choline PET-CT]:::action F --> G[Assess bone, soft tissue, nodal involvement]:::outcome D -->|PSA <10 & Gleason <7| H[Consider clinical judgment]:::action ``` **Warning:** Bone scan (Tc-99m MDP) is becoming obsolete for prostate cancer staging due to low sensitivity and specificity. It should NOT be used as first-line imaging in modern practice. **Mnemonic:** **PSMA-PET** = **P**rostate-**S**pecific **M**embrane **A**ntigen **P**ositron **E**mission **T**omography — the most specific and sensitive modality for detecting PCa metastases. [cite:Harrison 21e Ch 91; NCCN Prostate Cancer Guidelines 2023]